The STD diagnostics Market size was valued at USD 10.05 billion in 2023 and is expected to grow to USD 17.52 billion by 2031 and grow at a CAGR of 7.2% over the forecast period of 2024-2031.
STD stands for sexually transmitted diseases, also known as venereal diseases (VDs), which are typically communicated by the use of contaminated needles for drugs, breastfeeding or giving birth to a baby, blood transfusions, and sexual activity. These illnesses do not have any symptoms and are only discovered through various tests such as blood tests, urine samples, or fluid samples. Antibiotics and antiviral medications can be used to treat STDs brought on by bacteria. Absorbance microplate readers, flow cytometers, scattering machines, and immunochromatographic assays are a few of the tools utilized to identify the condition.
Get more information on STD diagnostics Market - Request Sample Report
The market for sexually transmitted diseases (STD) testing is expanding as a result of increased public awareness as well as patient education. Additionally, it is projected that a rise in STD prevalence around the globe, patient awareness raised through education programs, and a surge in government initiatives will fuel market expansion. In the last ten years, both the prevalence and the number of STD incidences have significantly increased.
KEY DRIVERS:
Increasing Research and Development
Rising STD Incidence
One of the main factors propelling the STD diagnostics market is the global increase in the prevalence of sexually transmitted illnesses. Unprotected sexual activity, evolving sexual behaviors, ignorance, and a lack of proper healthcare infrastructure are some of the factors that contribute to the increased prevalence of STDs and the need for accurate diagnosis.
RESTRAIN
Increasing Demand of Self Testing
Technological developments
There have been considerable breakthroughs in diagnostic technology that have affected the STD diagnostics market. Nucleic acid amplification tests (NAATs), which offer improved sensitivity and specificity, have supplemented or replaced conventional techniques like culture-based testing. Point-of-care tests (POCTs), which enable quick and practical testing in a variety of healthcare settings, have also gained popularity.
OPPORTUNITY:
Targeted testing solutions
Home Testing Kits
In recent years, the availability of STD testing kits for home use has grown in popularity. With the use of these kits, people can do self-tests in the comfort of their own homes and receive the findings without going to a medical facility. Home testing kits' ease of use and privacy offer a significant possibility for market expansion.
CHALLENGES:
Access to healthcare is restricted
Social Hurdles and Stigma
People may be discouraged from getting tested or receiving treatment due to the stigma attached to STDs, which could have an impact on the market's expansion.
An unprecedented global public health threat, the COVID-19 pandemic is expected to have a detrimental effect on the STD testing market. The prevalence of sexually transmitted infections was high before the pandemic, although it has since dropped as a result of STD testing. Due to difficulties in health care and services for testing for sexually transmitted infections during the early months of the COVID-19 epidemic, there were fewer reports of STIs. To maintain the supply of personal protective equipment and lower the exposure risks for patients and clinical personnel, preventive services were reduced, and many non-urgent visits were severely postponed or switched to virtual platforms.
The World Health Organisation determined that COVID-19 can be classified as a pandemic on March 11, 2020. Additionally, only a small number of vaccinations have been given emergency authorization for the treatment or prevention of COVID-19. As a result, social isolation is seen as the most crucial step in halting the disease's transmission. Furthermore, a few nations around the world have implemented statewide lockdowns to preserve social distancing.
Ukraine has the second-highest incidence of HIV/AIDS in Eastern Europe, with a general prevalence of 1.2 %, a prevalence of 22% among injecting drug users, and a prevalence of 7.6% among males who have sex with other men. During the current crisis, antiretroviral treatment (ART) has become scarce. High-risk behaviors, such as risky drug injection techniques and unsafe sex, may also rise, raising the possibility of developing new HIV infections. The issue on the inflation front is not yet gone due to the uncertainty about how Russia's conflict with Ukraine will play out this year and the war's role in causing global instability. Inflation of food and gasoline will continue to be a significant economic issue. Consumer confidence and spending will be impacted by higher retail inflation.
IMPACT OF ONGOING RECESSION
The government's efforts to control inflation by raising interest rates will limit the creation of new jobs, which will affect economic activity and growth. Because of concerns about inflation and decreased demand, businesses are delaying investments, which will result in lower capital spending. The developed markets appear ready to experience a recession due to weaker growth and excessive inflation.
Contrary to substantial increases for newborns and children under five, there is minimal evidence that youth death rates increase during economic crises. When there is a crisis, young people's general levels of poor health tend to grow, with increases in sexually transmitted illnesses in particular. (STDs) and diseases linked to substance usage. There is some evidence that general health service use is dropping; teenagers and young adults may be particularly affected by this.
By Product
Instruments and Services
Consumables
Software
By Technology
Immunoassay
Others
By Application
CT/NG testing
Syphilis testing
PCR testing
Non-PCR testing
Gonorrhea testing
HSV testing
PCR testing
Non-PCR testing
HPV testing
HIV testing
Ureaplasma & Mycoplasma testing
Trichomonas
VZV testing
PCR testing
Non-PCR testing
By Location of Testing
Laboratory Testing
Commercial/Private labs
Public Health Labs
Point of Care Testing
The regions of the STD diagnostics market are North America, Asia-Pacific, Central America, Latin America, the Middle East, and Africa. The regional study indicates that the Asia-Pacific area will probably continue to hold a substantial market share in 2023 and beyond. An increase in STI cases, an increase in the youth population, a lack of knowledge, and growing government activities are driving the Asia-Pacific STD testing market.
In contrast, North America will see significant development over the next several years due to the presence of key companies, the accessibility of cutting-edge products, and the growing use of point-of-care testing.
Need any customization research on STD diagnostics Market - Enquiry Now
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin American
The Major Players are Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMérieux SA, Thermo Fisher Scientific Inc., Danaher Corporation, Quide! Corporation, Hologic, Inc., Bio-Rad Laboratories, Inc., QIAGEN, DiaSorin S.p.A, Grifols S.A. and other players.
Becton, Dickinson, and Company, a new analytic instrument option for the BD COR System, announced the U.S. introduction of their new Tully automated, high-throughput infectious disease molecular diagnostics platform in May 2022.
The test is a single test that can identify the three non-viral STIs that are most common.
Trichomonas vaginalis (TV), Neisseria gonorrhoeae (GC), and The Chlamydia trachomatis (CT). The poor patient outcomes associated with these three STIs might vary from pregnancy difficulties to an elevated risk of HIV.
Report Attributes | Details |
Market Size in 2023 | US$ 10.05 Bn |
Market Size by 2031 | US$ 17.52 Bn |
CAGR | CAGR of 7.2% From 2024 to 2031 |
Base Year | 2023 |
Forecast Period | 2024-2031 |
Historical Data | 2020-2022 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
Key Segments | • By Product (Instruments and Services, Consumables, Software) • By Technology (Immunoassay, Molecular Diagnostics, Other) • By Application (CT/NG testing, Syphilis testing (PCR testing, Non-PCR testing), Gonorrhea testing, HSV testing (PCR testing, Non-PCR testing), HPV testing, HIV testing, Ureaplasma & Mycoplasma testing, Trichomonas, VZV testing (PCR testing, Non-PCR testing)) • By Location of Testing (Laboratory Testing (Commercial/Private labs, Public Health Labs), Point of Care Testing) |
Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
Company Profiles | Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Quide! Corporation (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), DiaSorin S.p.A (Italy), Grifols S.A. |
Key Drivers | • Increasing Research and Development • Rising STD Incidence |
Market Opportunities | • Targeted testing solutions • Home Testing Kits |
Ans: The STD Diagnostics Market is expected to grow at a CAGR of 7.2% by 2031.
Ans: The STD Diagnostics Market size was USD 10.05 billion in 2023 and is expected to Reach USD 17.52 billion by 2031.
Ans: One of the main factors propelling the STD diagnostics market is the global increase in the prevalence of sexually transmitted illnesses.
Ans: There have been considerable breakthroughs in diagnostic technology that have affected the STD diagnostics market.
Ans: The Asia Pacific region holds the largest market share and is expected to maintain its dominance in the coming forecast period.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of COVID-19
4.2 Impact of the Russia-Ukraine War
4.3 Impact of Ongoing Recession
4.4 Introduction
4.4.1 Impact on major economies
4.4.1.1 US
4.4.1.2 Canada
4.4.1.3 Germany
4.4.1.4 France
4.4.1.5 United Kingdom
4.4.1.6 China
4.4.1.7 Japan
4.4.1.8 South Korea
4.4.1.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. STD Diagnostics Market Segmentation, By Product
8.1 Instruments and Services
8.2 Consumables
8.3 Software
9. STD Diagnostics Market Segmentation, By Technology
9.1 Immunoassay
9.2 Molecular Diagnostics
9.3 Others
10. STD Diagnostics Market Segmentation, By Application
10.1 CT/NG testing
10.2 Syphilis testing
10.2.1 PCR testing
10.2.2 Non-PCR testing
10.3 Gonorrhea testing
10.4 HSV testing
10.4.1 PCR testing
10.4.2 Non-PCR testing
10.5 HPV testing
10.6 HIV testing
10.6 Ureaplasma & Mycoplasma testing
10.7 Trichomonas
10.8 VZV testing
10.8.1 PCR testing
10.8.2 Non-PCR testing
11. STD Diagnostics Market Segmentation, By Location of Testing
11.1 Laboratory Testing
11.1.1 Commercial/Private labs
11.1.2 Public Health Labs
11.2 Point of Care Testing
12. Regional Analysis
12.1 Introduction
12.2 North America
12.2.1 North America The STD diagnostics market by Country
12.2.2North America The STD diagnostics market by Type
12.2.3 North America The STD Diagnostics Market by Location of Testing
12.2.4 North America The STD diagnostics market by Testing Device
12.2.5 USA
12.2.5.1 USA The STD diagnostics market by Type
12.2.5.3 USA The STD diagnostics market by Location of Testing
12.2.5.4 USA The STD diagnostics market by Testing Device
12.2.6 Canada
12.2.6.1 Canada The STD diagnostics market by Type
12.2.6.3 Canada The STD diagnostics market by Location of Testing
12.2.6.4 Canada The STD diagnostics market by Testing Device
12.2.7 Mexico
12.2.7.1 Mexico The STD diagnostics market by Type
12.2.7.3 Mexico The STD diagnostics market by Location of Testing
12.2.7.4 Mexico The STD diagnostics market by Testing Device
12.3 Europe
12.3.1 Europe The STD diagnostics market by Country
1.3.3.2 Europe The STD diagnostics market by Type
12.3.3 Europe The STD diagnostics market by Location of Testing
12.3.4 Europe The STD diagnostics market by Testing Device
12.3.5 Germany
12.3.5.1 Germany The STD diagnostics market by Type
12.3.5.2 Germany The STD diagnostics market by Location of Testing
12.3.5.3 Germany The STD diagnostics market by Testing Device
12.3.6 UK
12.3.6.1 UK The STD diagnostics market by Type
12.3.6.2 UK The STD diagnostics market by Location of Testing
12.3.6.3 UK The STD diagnostics market by Testing Device
12.3.7 France
12.3.7.1 France The STD diagnostics market by Type
12.3.7.2 France The STD diagnostics market by Location of Testing
12.3.7.3 France The STD diagnostics market by Testing Device
12.3.8 Italy
12.3.8.1 Italy The STD diagnostics market by Type
12.3.8.2 Italy The STD diagnostics market by Location of Testing
12.3.8.3 Italy The STD diagnostics market by Testing Device
12.3.9 Spain
12.3.9.1 Spain The STD diagnostics market by Type
12.3.9.2 Spain The STD diagnostics market by Location of Testing
12.3.9.3 Spain The STD diagnostics market by Testing Device
12.3.10 The Netherlands
12.3.10.1 Netherlands The STD diagnostics market by Type
12.3.10.2 Netherlands The STD diagnostics market by Location of Testing
12.3.10.3 Netherlands The STD diagnostics market by End-use
12.3.12 Rest of Europe
12.3.12.1 Rest of Europe The STD diagnostics market by Type
12.3.12.2 Rest of Europe The STD diagnostics market by Location of Testing
12.3.12.3 Rest of Europe The STD diagnostics market by Testing Device
12.4 Asia-Pacific
12.4.1 Asia Pacific The STD diagnostics market by Country
12.4.2 Asia Pacific The STD diagnostics market by Type
12.4.3 Asia Pacific The STD diagnostics market by Location of Testing
12.4.4 Asia Pacific The STD diagnostics market by Testing Device
12.4.5 Japan
12.4.5.1 Japan The STD diagnostics market by Type
12.4.5.2 Japan The STD diagnostics market by Location of Testing
12.4.5.3 Japan The STD diagnostics market by Testing Device
12.4.6 South Korea
12.4.6.1 South Korea The STD diagnostics market by Type
12.4.6.2 South Korea The STD diagnostics market by Location of Testing
12.4.6.3 South Korea The STD diagnostics market by Testing Device
12.4.7 China
12.4.7.1 China The STD diagnostics market by Type
12.4.7.2 China The STD diagnostics market by Location of Testing
12.4.7.3 China The STD diagnostics market by Testing Device
12.4.8 India
12.4.8.1 India The STD diagnostics market by Type
12.4.8.2 India The STD diagnostics market by Location of Testing
12.4.8.3 India The STD diagnostics market by Testing Device
12.4.9 Australia
12.4.9.1 Australia The STD diagnostics market by Type
12.4.9.2 Australia The STD diagnostics market by Location of Testing
12.4.9.3 Australia The STD diagnostics market by Testing Device
12.4.10 Rest of Asia-Pacific
12.4.10.1 APAC The STD diagnostics market by Type
12.4.10.2 APAC The STD diagnostics market by Location of Testing
12.4.10.3 APAC The STD diagnostics market by Testing Device
12.5 The Middle East & Africa
12.5.1 The Middle East & Africa The STD diagnostics market by Country
12.5.2 The Middle East & Africa The STD diagnostics market by Type
12.5.3 The Middle East & Africa The STD diagnostics market by Location of Testing
12.5.4 The Middle East & Africa The STD diagnostics market by Testing Device
12.5.6 Israel
12.5.6.1 Israel The STD diagnostics market by Type
12.5.6.2 Israel The STD diagnostics market by Location of Testing
12.5.6.3 Israel The STD diagnostics market by Testing Device
12.5.6 UAE
12.5.6.1 UAE The STD diagnostics market by Type
12.5.6.2 UAE The STD diagnostics market by Location of Testing
12.5.6.3 UAE The STD diagnostics market by Testing Device
12.5.7 South Africa
12.5.7.1 South Africa The STD diagnostics market by Type
Product Type
12.5.7.2 South Africa The STD diagnostics market by Location of Testing
12.5.7.3 South Africa The STD diagnostics market by Testing Device
12.5.8 Rest of Middle East & Africa
12.5.8.1 Rest of Middle East & Asia The STD diagnostics market by Type
12.5.8.2 Rest of Middle East & Asia The STD diagnostics market Location of Testing.
12.5.8.3 Rest of Middle East & Asia The STD diagnostics market by Testing Device
12.6 Latin America
12.6.1 Latin America The STD diagnostics market by Country
12.6.2 Latin America The STD diagnostics market by Type
12.6.3 Latin America The STD diagnostics market by Location of Testing
12.6.4 Latin America The STD diagnostics market by Testing Device
12.6.5 Brazil
12.6.5.1 Brazil The STD diagnostics market by Type
12.6.5.2Brazil The STD diagnostics market by Location of Testing
12.6.5.3 Brazil The STD diagnostics market by Testing Device
12.6.6 Argentina
12.6.6.1 Argentina The STD diagnostics market by Type
12.6.6.2 Argentina The STD diagnostics market by Location of Testing
12.6.6.3 Argentina The STD diagnostics market by Testing Device
12.6.7 Rest of Latin America
12.6.7.1 Rest of Latin America The STD diagnostics market by Type
12.6.7.2 Rest of Latin America The STD diagnostics market by Location of Testing
12.6.7.3 Rest of Latin America The STD diagnostics market by Testing Device
13. Company Profile
13.1 Abbott Laboratories (US)
13.1.1 Market Overview
13.1.2 Financials
13.1.3 Product/Services/Offerings
13.1.4 SWOT Analysis
13.1.5 The SNS View
13.2 F. Hoffmann-La Roche Ltd. (Switzerland)
13.2.1 Market Overview
13.2.2 Financials
13.2.3 Product/Services/Offerings
13.2.4 SWOT Analysis
13.2.5 The SNS View
13.3 bioMérieux SA (France)
13.4.1 Market Overview
13.3.2 Financials
13.3.3 Product/Services/Offerings
13.3.4 SWOT Analysis
13.3.5 The SNS View
13.4 Thermo Fisher Scientific Inc. (US)
13.4.1 Market Overview
13.4.2 Financials
13.4.3 Product/Services/Offerings
13.4.4 SWOT Analysis
13.4.5 The SNS View
13.5 Danaher Corporation (US)
13.5.1 Market Overview
13.5.2 Financials
13.5.3 Product/Services/Offerings
13.5.4 SWOT Analysis
13.5.5 The SNS View
13.6 Quide! Corporation(US)
13.6.1 Market Overview
13.6.2 Financials
13.6.3 Product/Services/Offerings
13.6.4 SWOT Analysis
13.6.5 The SNS View
13.7 Hologic, Inc. (US).
13.7.1 Market Overview
13.7.2 Financials
13.7.3 Product/Services/Offerings
13.7.4 SWOT Analysis
13.7.5 The SNS View
13.8 Bio-Rad Laboratories, Inc. (US)
13.8.1 Market Overview
13.8.2 Financials
13.8.3 Product/Services/Offerings
13.8.4 SWOT Analysis
13.8.5 The SNS View
13.9 QIAGEN (Netherlands)
13.9.1 Market Overview
13.9.2 Financials
13.9.3 Product/Services/Offerings
13.9.4 SWOT Analysis
13.9.5 The SNS View
13.10 DiaSorin S.p.A (Italy),
13.10.1 Market Overview
13.10.2 Financials
13.10.3 Product/Services/Offerings
13.10.4 SWOT Analysis
13.10.5 The SNS View
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share Analysis
14.3 Recent Developments
15. USE Cases and Best Practices
16. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Oncology Drugs Market size was USD 221.38 Billion in 2023 and is expected to Reach USD 525.08 Billion by 2031 and grow at a CAGR of 11.4% over the forecast period of 2024-2031.
The Ureteroscope Market Size was valued at USD 1,056.2 Million in 2023 and is expected to reach USD 1,685.14 Million by 2032 and grow at a CAGR of 5.54% over the forecast period 2024-2032.
The Healthcare Asset Management Market size was valued at USD 25.7 billion in 2023, and is expected to reach USD 166.82 billion by 2032 and grow at a CAGR of 23.1% over the forecast period 2024-2032.
The Radiology Information Systems Market Size was valued at USD 1.16 billion in 2023 and is expected to reach USD 2.64 billion by 2032, and grow at a CAGR of 9.60% over the forecast period 2024-2032.
The Mononucleosis Diagnostic Market size was estimated at USD 1.7 billion in 2022 and is expected to reach USD 3.2 billion by 2030 with a growing CAGR of 8.6% during the forecast period of 2023-2030.
The Clinical Trial Imaging Market Size was valued at USD 1.2 billion in 2023 and is expected to reach USD 2.14 billion by 2031 and grow at a CAGR of 7.5% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone